OTONOMY
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch OTONOMY and buy or sell other stocks, ETFs, and their options commission-free!About OTIC
Otonomy, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.
CEODavid A. Weber, PhD
CEODavid A. Weber, PhD
Employees—
Employees—
HeadquartersWilmington, Delaware
HeadquartersWilmington, Delaware
Founded2008
Founded2008
Employees—
Employees—
OTIC Key Statistics
Market cap485.80K
Market cap485.80K
Price-Earnings ratio-0.01
Price-Earnings ratio-0.01
Dividend yield—
Dividend yield—
Average volume503.96K
Average volume503.96K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$2.54
52 Week high$2.54
52 Week low$0.0075
52 Week low$0.0075
Stock Snapshot
As of today, OTONOMY(OTIC) shares are valued at $0.01. The company's market cap stands at 485.8K, with a P/E ratio of -0.01.
On 2025-12-23, OTONOMY(OTIC) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for OTONOMY(OTIC) stock has reached 0, versus its average volume of 503.96K.
Over the past 52 weeks, OTONOMY(OTIC) stock has traded between a high of $2.54 and a low of $0.01.
Over the past 52 weeks, OTONOMY(OTIC) stock has traded between a high of $2.54 and a low of $0.01.
People also own
Based on the portfolios of people who own OTIC. This list is generated using Robinhood data, and it’s not a recommendation.